Page 91 - 《中国药房》2025年11期
P. 91

Evidence  from  a  retrospective  analysis  in  a  cohort  of      cer[J]. Value Health,2011,14(6):836-845.
              Chinese patients[J]. Front Endocrinol (Lausanne),2022,  [17]  RUI M J,FEI Z Y,WANG Y C,et al. Cost-effectiveness
              13:947443.                                          analysis  of  sintilimab  +  chemotherapy  versus  camreli‐
          [ 4 ]  SOCINSKI M A,OBASAJU C,GANDARA D,et al. Cur‐     zumab  +  chemotherapy  for  the  treatment  of  first-line  lo‐
              rent and emergent therapy options for advanced squamous   cally  advanced  or  metastatic  nonsquamous  NSCLC  in
              cell lung cancer[J]. J Thorac Oncol,2018,13(2):165-183.  China[J]. J Med Econ,2022,25(1):618-629.
          [ 5 ]  LAU S C M,PAN Y W,VELCHETI V,et al. Squamous   [18]  SHAO  T  H,REN  Y  N,ZHAO  M  Y,et  al.  Cost-
              cell lung cancer:current landscape and future therapeutic   effectiveness  analysis  of  camrelizumab  plus  chemo‐
              options[J]. Cancer Cell,2022,40(11):1279-1293.      therapy  as  first-line  treatment  for  advanced  squamous
          [ 6 ]  国家卫生健康委办公厅 . 关于印发原发性肺癌等 18 个                     NSCLC  in  China[J].  Front  Public  Health,2022,10:
              肿瘤诊疗规范(2018年版)的通知[EB/OL].(2018-12-13)               912-921.
              [2024-11-10]. http://www.nhc.gov.cn/yzygj/s7659/201812/  [19]  刘国强,康朔,王欣晨.帕博利珠单抗一线治疗PD-L1高
              b21802b199814ab7b1219b87de0cae51.shtml.             表达的晚期非小细胞肺癌的药物经济学评价[J].中国药
          [ 7 ]  LI X L,SHAO C S,SHI Y F,et al. Lessons learned from   房,2021,32(11):1351-1356.
              the  blockade  of  immune  checkpoints  in  cancer  immuno‐  [20]  齐冉,聂旭阳,刘旭婷,等. 斯鲁利单抗联合化疗方案一
              therapy[J]. J Hematol Oncol,2018,11(1):31.          线治疗广泛期小细胞肺癌的药物经济学评价[J]. 中国药
          [ 8 ]  DHILLON S. Penpulimab:first approval[J]. Drugs,2021,  房,2023,34(11):1368-1373.
              81(18):2159-2166.                              [21]  NAFEES B,LLOYD A J,DEWILDE S,et al. Health state
          [ 9 ]  ZHONG H,SUN S J,CHEN J H,et al. First-line penpu‐  utilities  in  non-small  cell  lung  cancer:an  international
              limab combined with paclitaxel and carboplatin for meta‐  study[J]. Asia Pac J Clin Oncol,2017,13(5):e195-e203.
              static  squamous  non-small-cell  lung  cancer  in  China   [22]  ALLEMANI C,WEIR H K,CARREIRA H,et al. Global
              (AK105-302):a  multicentre,randomised,double-blind,  surveillance of cancer survival 1995-2009:analysis of in‐
              placebo-controlled phase 3 clinical trial[J]. Lancet Respir   dividual data for 25 676 887 patients from 279 population-
              Med,2024,12(5):355-365.                             based registries in 67 countries (CONCORD-2)[J]. Lan‐
          [10]  HAN B,CHEN J,WANG Z,et al. Penpulimab in combi‐   cet,2015,385(9972):977-1010.
              nation  with  anlotinib  as  first-line  treatment  in  advanced   [23]  ALLEMANI  C,MATSUDA  T,DI  CARLO  V,et  al.
              nonsquamous non-small-cell lung cancer[J]. J Clin Oncol,  Global  surveillance  of  trends  in  cancer  survival  2000-14
              2021,39 (15):e21072-e21072.                        (CONCORD-3):analysis  of  individual  records  for
          [11]  中国医师协会肿瘤医师分会,中国医疗保健国际交流促                          37  513  025  patients  diagnosed  with  one  of  18  cancers
              进会肿瘤内科分会 .Ⅳ期原发性肺癌中国治疗指南:                            from  322  population-based  registries  in  71  countries[J].
              2023年版[J].中国综合临床,2023,39(3):161-190.                Lancet,2018,391(10125):1023-1075.
          [12]  中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会                    [24]  CARLISLE  J  W,STEUER  C  E,OWONIKOKO  T  K,
              (CSCO)免疫检查点抑制剂临床应用指南:2024[M]. 北                     et  al.  An  update  on  the  immune  landscape  in  lung  and
              京:人民卫生出版社,2024:54.                                  head and neck cancers[J]. CA Cancer J Clin,2020,70(6):
          [13]  中华医学会肿瘤学分会,中华医学会杂志社 . 中华医学                        505-517.
              会肺癌临床诊疗指南:2023 版[J]. 中华肿瘤杂志,2023,              [25]  XU L Z,CHEN M S,ANGELL B,et al. Establishing cost-
              45(7):539-574.                                      effectiveness  threshold  in  China:a  community  survey  of
          [14]  刘国恩. 中国药物经济学评价指南2020[M]. 北京:中国                    willingness  to  pay  for  a  healthy  life  year[J].  BMJ  Glob
              市场出版社,2020:27-115.                                  Health,2024,9(1):e013070.
          [15]  刘家一,李伟 . R 语言实例解析肿瘤治疗药物经济学评                  [26]  ZHAO Z X,YANG Y,WU W J,et al. Willingness to pay
              价的分区生存模型[J]. 数理医药学杂志,2024,37(4):                    for cancer prevention versus treatment in China:implica‐
              240-251.                                            tions for cost-effectiveness threshold[J]. Expert Rev Phar‐
          [16]  GOULART  B,RAMSEY  S. A  trial-based  assessment  of   macoecon Outcomes Res,2024,24(1):155-160.
              the cost-utility of bevacizumab and chemotherapy versus       (收稿日期:2024-12-06  修回日期:2025-05-12)
              chemotherapy alone for advanced non-small cell lung can‐                            (编辑:孙 冰)





          中国药房  2025年第36卷第11期                                              China Pharmacy  2025 Vol. 36  No. 11    · 1369 ·
   86   87   88   89   90   91   92   93   94   95   96